Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olanzapine/ondansetron

Drug Profile

Olanzapine/ondansetron

Alternative Names: Ondansetron/olanzapine; TO-2060

Latest Information Update: 05 May 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TransOral Pharmaceuticals
  • Class Benzodiazepines; Carbazoles; Imidazoles; Small molecules
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alcoholism

Most Recent Events

  • 02 Feb 2009 Novacea has merged with Transcept Pharmaceuticals to form Transcept Pharmaceuticals Inc
  • 08 May 2008 Interim efficacy data from a phase I trial in Alcoholism presented at the 161st Annual Meeting of the American Psychiatric Association (APA-2008)
  • 22 Jun 2007 Phase-I clinical trials in Alcoholism in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top